While immune hemolysis due to donor isohemagglutinin (IH) production often complicates minor ABO incompatible peripheral blood hematopoietic stem cell transplantation (PBSCT), it is not known if this occurs with umbilical cord blood transplantation (UCBT). We compared IH production and hemolysis following minor ABO allogeneic PBSCT and UCBT. We reviewed 24 ABO minor incompatible allogeneic PBSCTs and 14 ABO minor incompatible UCBTs. Patients were evaluated for donor-derived IH by reverse ABO grouping. Evaluation of hemolysis was based on clinical and laboratory findings of anemia associated with increased RBC transfusion need, concomitant with the appearance of donor-derived IH. Of the 24 ABO minor incompatible allogeneic PBSCTs, 15 produced donor-derived IH from 6 to 88 days following transplantation, with seven of 15 patients exhibiting clinically evident hemolysis. There was no significant difference in days to leukocyte engraftment or infused CD34 cells in patients with or without donorderived IH. None of the 14 patients receiving ABO incompatible UCBTs showed evidence of donor-derived IH following transplantation with a median follow-up of 60 days. We conclude that donor IHs are not produced in patients undergoing minor ABO incompatible UCBTs suggesting fundamental immunologic differences between allogeneic PBSCT and UCBT.
Introduction
ABO incompatibility between donor and recipient occurs in 30-40% of patients undergoing allogeneic bone marrow or peripheral blood stem cell transplantation (PBSCT). 1 Incompatibility may be classified as major, minor or both. Major ABO incompatibility occurs when the transplant recipient has naturally occurring IHs directed against the corresponding donor red cell antigens. The following donor/recipient pairings define major ABO incompatibility: AB-A, B or O; A-B or O; B-A or O. Minor ABO mismatch occurs when the donor has, or has the potential to make, IHs against recipient red cell antigens. Thus, the interchange of donor and recipient in a major ABO mismatch results in a minor mismatch. The pairings of A-B or B-A represent both a major and minor (bidirectional) mismatch.
A minor ABO mismatch occurs in 15-20% of HLAmatched PBSCTs. 1 The significance of this type of mismatch is that patients undergoing ABO incompatible allogeneic bone marrow or stem cell transplantation are at risk for RBC hemolysis. Significant hemolysis due to the production of IHs occurs in approximately 10-15% of minor ABO mismatched grafts. This hemolysis may be immediate, due the presence of preformed IgM and/or IgG IHs or delayed, due to antibody production from passenger B-lymphocytes in the transplant inoculum. In the case of immediate hemolytic reactions, pretransplant IH titers have been shown to predict the incidence and severity of hemolysis. 2 Typically, delayed hemolysis occurs transiently, 7-14 days after transplantation. However, delayed hemolysis after minor ABO-incompatible PBSCT can be severe and even fatal. 1, [3] [4] [5] Based on recent studies and case reports of hemolysis occurring after minor or bidirectional ABO-incompatible PBSCT, it has been suggested that PBSC recipients are at a greater risk for this complication than recipients of bone marrow or umbilical cord blood. [2] [3] [4] 6 The frequency of occurrence and severity of the hemolysis has been suggested to be due to the larger number of B-lymphocytes contained in the inoculum in PBSCT. 2, 3, [5] [6] [7] The occurrence of hemolysis in the setting of minor ABO incompatible UCBTs is not known. Notably, IHs are not present at birth, but rather are produced as a result of ingestion or inhalation of exogenous antigens during the first 2 years of life. 8 Thus, IH production may be considerably different after transplants utilizing umbilical cord blood compared to bone marrow or peripheral blood stem cell transplants. Therefore, we assessed and compared the frequency of donor-derived IH production, and clinically apparent hemolysis following minor ABO incompatible allogeneic PBSCT and UCBT.
Materials and methods

Transplant protocols and patient eligibility
The Institutional Review Board of Case Western Reserve University/University Hospitals of Cleveland approved the clinical protocols for UCB and PBSC transplantation. Informed consent was obtained from all patients. Patients were eligible for treatment per HLA-identical allogeneic PBSCTs clinical trials if allogeneic stem cell transplantation was clinically indicated. Patients were eligible for enrollment in UCB clinical trials if they had stable hematologic disease and lacked an HLA-identical related or unrelated donor, or had unstable disease, lacked a related donor, and an HLA-matched unrelated bone marrow donor could not be identified within 6-8 weeks. All adult patients consecutively transplanted with UCB at this institution since 4/1998 and all HLA identical allogeneic PBSCT recipients treated since 2/1996 were included in this retrospective comparative analysis.
Graft selection
Preliminary searches of UCB banks were performed using the patient's HLA phenotype, based on serologic typing before year 2000 for class I HLA-A and HLA-B antigens and low-resolution DNA typing for class II HLA alleles. High-resolution molecular typing for HLA-DRB1 alleles was performed as confirmatory typing. After year 2000, DNA typing was routinely performed for class I HLA-A, HLA-B, HLA-C alleles. The HLA identical allogeneic PBSCT grafts were matched at 6/6 HLA loci (HLA-A, -B and DRB1), containing a minimum 20 Â 10 7 mononuclear cells/kg recipient body weight. Preferred UCB units were those matched at 3/6 HLA loci or better and containing a minimum prefreeze cell dose of 1 Â 10 7 nucleated cells/kg recipient body weight. The mean cell dose (7s.d.) infused for UCBTs was 2.0670.898 cells/kg, which did not differ significantly from the prefreeze dose (mean ¼ 2.9070.212; P-value 0.086 by the paired t-test). Units of umbilical-cord blood were not depleted of T lymphocytes. Some units were reduced in volume and depleted of red cells with hetastarch before freezing, as previously described. 9 
Patient population
We retrospectively reviewed 89 HLA-identical related allogeneic PBSCTs and 44 UCBTs at University Hospitals of Cleveland, between February 1996 and March 2003. From this group, recipients exhibiting minor ABO incompatibility were selected, compared and analyzed in detail for differences in immunohematologic findings. The study group consisted of 24 ABO minor (including four major/ minor) incompatible PBSCTs and 14 ABO minor (including two major/minor) incompatible UCBTs (Table 1) . Patients underwent transplantation for treatment of acute leukemia, chronic leukemia, myelodysplasia, nonHodgkin's lymphoma and Glanzmann's thrombasthenia ( Table 1 ). The 24 patients in the PBSCT group underwent HLA-identical related transplants. The 14 patients in the UCBT group were all unrelated transplants with HLA mismatches of one (n ¼ 1), two (n ¼ 7) or three (n ¼ 2) antigens.
Preparative regimens and transplant supportive care
Disease status for leukemia was categorized according to the International Bone Marrow Transplant Registry (IBMTR) criteria. 10 Conditioning regimens for PBSCT recipients diagnosed with AML and CML included, cyclophosphamide (Cy) 120 mg/kg with either total body irradiation (TBI) 1200 cGy 11 or busulfan (Bu) 16 mg/kg (or adjusted-dose AUC). 12 Patients with ALL received TBI 1320 cGy and etoposide 60 mg/kg. 13 All UCB patients received either TBI/Cy or Bu/Cy conditioning and antithymocyte globulin (ATGAM; Pharmacia-Upjohn, Kalamazoo, MI, USA) 90 mg/kg over 3 days (day À3 to À1) prior to UCB infusion. 9 Supportive care included administration of recombinant granulocyte colony-stimulating factor (Filgrastim, Amgen, Thousand Oaks, CA, USA) subcutaneously daily, starting at day of graft infusion (day 0) for UCB patients (10 mg/kg/day), and day þ 7, after completion of methotrexate (MTX) administration, for PBSCT recipients (5 mg/kg/day), and continued daily until full donor-derived neutrophil recovery was achieved.
GVHD prophylaxis
Prophylactic regimens for graft-versus-host disease (GVHD) included cyclosporine (CSA) (day À2 through day þ 180) combined with methylprednisolone (MP) at a dose of 1 mg/kg/day (day þ 5 through þ 13) in the UCB Lack of isohemagglutinin production M Snell et al group, or modified short-course MTX (10 mg/m 2 day þ 1, þ 3 and þ 6) in the HLA-identical allogeneic PBSCT group. Acute GVHD (aGVHD) was scored weekly using standardized guidelines. 14 Patients surviving more than 100 days after transplantation were evaluated and graded for chronic GVHD (cGVHD) according to standard criteria. 15 Acute GVHD (grade II or higher) was treated with MP, 2-10 mg/kg/day (IV or PO) in three divided doses for 7-14 days, then tapered by 0.5 mg/kg/day every 5 days. An alternative regimen of methylprednisolone 500 mg/m 2 /dose q 12 h Â 2 doses, repeated every 48-72 h for up to four courses was also used. Corticosteroid-resistant aGVHD and cGVHD were treated with second-line immunosuppressive agents according to institutional protocols. Hematopoietic engraftment was defined as the first of three consecutive days with an Absolute Neutrophil Count (ANC)4500/ml. Chimerism analysis of peripheral blood mononuclear cells was performed in all patients and full donor chimerism (498% donor) was noted in all patients who survived 428 days and engrafted. 1, 16 Results Table 2 ). None of the 14 patients who received UCBT developed persistent IHs attributable to antibody production by the graft on testing, ranging from day 7 to day 1303 post-transplant (Table 3) . In 2 of 14 cases the IH corresponding to the donor type was transiently, weakly positive. This was seen immediately following infusion of ABO incompatible platelets and likely represents passive infusion of IH. In one case, considered an outlier, a single positive (grade 2 þ ) reaction occurred, with eight previous and three subsequent negative reactions. This most likely represents a misinterpretation of results. 
Serological testing
Prevalence of donor-derived isohemagglutinins
Fifteen of the 24 patients with PBSCTs produced donorderived IHs. Initial detection of these IHs ranged from day 6 to day 88 following transplantation (mean ¼ 23 days, median ¼ 13 days), with median strength of 3 þ in the ID-MTS Gel reverse grouping assay (
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Prevalence of immune hemolysis
Immune hemolysis was observed in 15 of the 24 ABO minor incompatible allogeneic PBSCTs (Table 4) . Of these patients, seven developed clinically severe hemolysis with increased transfusion needs between day 7 and day 13 posttransplant. All hemolytic events were self-limited without any impairment in hematopoietic reconstitution and/or clinical course. In the 14 patients receiving minor ABO incompatible UCBTs, no evidence of immune hemolysis was observed.
Engraftment
All of the 24 PBSCT patients demonstrated WBC engraftment (as defined above), with time to engraftment ranging from 9 to 15 days (mean ¼ 12 days) ( Table 2 ). There was no significant difference in days to engraftment in patients with or without donor-derived IHs. Nine of 14 UCBT patients demonstrated WBC engraftment with days to engraftment ranging from 13 to 42 (mean ¼ 29) (Table 3) .
Discussion
Immune hemolysis occurring as a complication in patients receiving minor or bidirectional ABO incompatible hematopoietic stem cell transplantation may be severe and even fatal. As the IHs are not detected immediately posttransplant, but usually 7-14 days later, it is assumed that they are produced by viable donor lymphocytes transfused during transplantation and by cells derived from these lymphocytes. When levels of IH reach a critical quantity, hemolysis of recipient red blood cells typically occurs with abrupt onset. 17, 18 Similar syndromes have been reported in solid organ transplants in which 'passenger lymphocytes' produce IHs against recipient ABO antigens. 19 The operative mechanism for IH production is in vivo sensitization of donor memory B-lymphocytes before transfer to the recipient, so post-transplant donor-derived IH production is a secondary immune response. 20, 21 The IH production against the recipient red cells is only transient and its eventual disappearance may be due to high zone tolerance brought about by continued exposure of donor lymphocytes to A or B antigens in the recipient's plasma and tissues, or due to the effects of continued immunosuppression causing eradication of these lymphocytes. 22 Donor IH production was not identified in our study group undergoing minor ABO incompatible UCBTs, contrasting sharply from our experience in PBSCTs (0/14 vs 15/24 patients).
There are several possible reasons for the absence of delayed hemolysis in UCBTs. The absence may be attributable, at least in part, to the difference in donor population, the differences in the cellular components present in the donor grafts or the transplant protocols used. Whereas PBSCTs utilized matched sibling donors, all UCBT donors were unrelated to the recipients. This difference, however, would be expected to cause more hemolysis in the UCBT group rather than less, as was observed.
As mentioned previously, B lymphocytes are present in far greater numbers in PBSCTs than UCBTs. TheilgaardMonch, et al. assessed the lymphoid subsets in allogenic stem cell grafts and have shown that the absolute number of B lymphocytes infused was 2230.607313.83 Â 10 6 for PBSCTs, as compared to 111.34724.82 Â 10 6 for UCBTs suggesting that the decreased number of B lymphocytes may affect donor-specific IH production 23 (our institution does not routinely examine graft content for lymphocytes, however, the difference in lymphoid subsets noted in the aforementioned paper is similar to the 10-fold difference in minimal nucleated cell dose used in this study).
It is unlikely, however, that differences in cell dose alone can account for the lack of hemolysis seen in UCBTs. Donor derived IHs were detected at high levels (median 3 þ ) in PBSCT patients exhibiting hemolysis. If cell dose were the sole difference between these graft types, we should still detect IH production in UCBTs (albeit at a lower level than in PBSCTs). Furthermore, it is likely that some degree of hemolysis would occur in UCBTs, although again, at a lower (possibly subclinical) rate than in PBSCTs. Our data, however, showed no evidence that either of these events occurred.
Thus, there must be another difference between transplant types which can account for the lack of hemolysis in UCBTs. It is likely that the absence of IH production in UCBTs is due, at least in part, to differences in the 24 In PBSC grafts, a secondary immune response occurs when the memory IH-specific CD27( þ ) B lymphocytes are re-exposed to the recipient's A or B antigens, resulting in donor-specific IH production. Given that newborns have not been exposed to A or B antigens, a secondary IH-specific immune response would not be expected to occur in UCBTs. Additionally, any naive antirecipient IH-specific CD27(À) allogeneic B cells present in the umbilical cord blood grafts will mature in the hosts' ABO environment, resulting in tolerance or deletion of the A or B specific B lymphocytes and subsequently, lack of antirecipient isohemagglutinin production. It should be noted that production of antirecipient IHs from naive B cells probably does not occur in PBSCTs either, since donor-specific IHs are attributed to memory B cells present within the graft. Antirecipient IHs disappear over time in PBSCTs as the memory B cells become tolerant or are deleted and cannot be replaced by a replenishing population of naive antirecipient IH-specific B cells.
This raises the question of whether or not immature B cells in UCBT ever make any IHs. Our data show that, for example, an O(donor)-A(recipient) UCBT will never make anti-A. But will the maturing B cells eventually make anti-B in this case? In minor ABO incompatible PBSCTs, Lee et al. 25 have shown that titers of IHs against ABO antigens absent on both donor and recipient RBCs decreased post-transplant, and then rose again by day 59. This is felt to represent a transition from IH production by recipient B cells to production by maturing donor B cells. In our evaluation of minor ABO incompatible UCBTs, we did not see a change in the strength of the IH titers for such patients. However, these data were available for only a few patients. A more definitive answer to this question could be obtained by testing for a change in the profile of subtypes of IH against these ABO antigens (in cases where donor and recipient make different subtypes of the same IH). 26, 27 In summary, based on the preliminary observations in our study, the lack of IH production in UCBTs results in the absence of the severe and life-threatening complications of delayed hemolysis sometimes seen in minor ABO incompatible PBSCT. This finding represents another advantage of UCBT (in addition to previously described advantages, such as comparatively low occurrence and severity of GVHD 9 ), and highlights the fundamental immunologic differences between the two types of transplants. While the main goal of this paper was to present evidence for the lack of hemolysis in UCBTs, we have also attempted to provide a data-driven rationale to explain the underlying mechanisms of this phenomenon. We believe that further investigation to detail these mechanisms is warranted.
